One Stop Solution For In-Depth Market Research Reports
sales@sdki.us
Abbott
Nutricia (Danone Group)
Mead Johnson (Reckitt Benckiser)
Horizon Therapeutics plc
Nestlé
Bausch Health Companies, Inc.
Ultragenyx Pharmaceutical Inc.
Arcturus Therapeutics, Inc.
Acer Therapeutics
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Pipeline Analysis
5.3. Standard Guidelines for Approval of Drugs
5.4. Overview of Diagnostics approach for OTC Deficiency
5.5. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
6.3.1. Buphenyl
6.3.2. Ravicti
6.3.3. Ammonul
6.3.4. Dietary Supplements
6.3.5. Others
6.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product
7. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
7.3.1. Oral
7.3.2. Intravenous
7.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration
8. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel
9. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Region
10. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
10.2.1. Buphenyl
10.2.2. Ravicti
10.2.3. Ammonul
10.2.4. Dietary Supplements
10.2.5. Others
10.3. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
10.3.1. Oral
10.3.2. Intravenous
10.4. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
11.2.1. Buphenyl
11.2.2. Ravicti
11.2.3. Ammonul
11.2.4. Dietary Supplements
11.2.5. Others
11.3. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
11.3.1. Oral
11.3.2. Intravenous
11.4. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
12.2.1. Buphenyl
12.2.2. Ravicti
12.2.3. Ammonul
12.2.4. Dietary Supplements
12.2.5. Others
12.3. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
12.3.1. Oral
12.3.2. Intravenous
12.4. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
13.2.1. Buphenyl
13.2.2. Ravicti
13.2.3. Ammonul
13.2.4. Dietary Supplements
13.2.5. Others
13.3. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
13.3.1. Oral
13.3.2. Intravenous
13.4. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
14.2.1. Buphenyl
14.2.2. Ravicti
14.2.3. Ammonul
14.2.4. Dietary Supplements
14.2.5. Others
14.3. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
14.3.1. Oral
14.3.2. Intravenous
14.4. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share/Position Analysis, by Company (2019)
15.3. Company Profiles
15.3.1. Abbott
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Nutricia (Danone Group)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Mead Johnson (Reckitt Benckiser)
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Horizon Therapeutics plc
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Nestlé
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Bausch Health Companies, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Ultragenyx Pharmaceutical Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Arcturus Therapeutics, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Acer Therapeutics
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
[Report Description]
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market - Scope of the Report
The report on the global ornithine transcarbamylase (OTC) deficiency treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall market revenue of the global ornithine transcarbamylase (OTC) deficiency treatment market for the period 2018-2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global ornithine transcarbamylase (OTC) deficiency treatment market for the forecast period.
The report has been prepared after extensive primary and secondary research. Primary research involves bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global ornithine transcarbamylase (OTC) deficiency treatment market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomena in the global ornithine transcarbamylase (OTC) deficiency treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global ornithine transcarbamylase (OTC) deficiency treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global ornithine transcarbamylase (OTC) deficiency treatment market.
The report delves into the competitive landscape of the global ornithine transcarbamylase (OTC) deficiency treatment market. Key players operating in the global ornithine transcarbamylase (OTC) deficiency treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global ornithine transcarbamylase (OTC) deficiency treatment market that have been profiled in this report.
Key Questions Answered in Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Report
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market - Research Objectives and Research Approach
The comprehensive report on the global ornithine transcarbamylase (OTC) deficiency treatment market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, pipeline analysis, disease prevalence in key countries, Overview of Diagnostics Approach for OTC Deficiency, standard guidelines for approval of drugs, and impact of COVID-19 in global ornithine transcarbamylase (OTC) deficiency treatment market have been provided.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global ornithine transcarbamylase (OTC) deficiency treatment market in terms of product, route of administration, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2030 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global ornithine transcarbamylase (OTC) deficiency treatment market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Pipeline Analysis
5.3. Standard Guidelines for Approval of Drugs
5.4. Overview of Diagnostics approach for OTC Deficiency
5.5. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
6.3.1. Buphenyl
6.3.2. Ravicti
6.3.3. Ammonul
6.3.4. Dietary Supplements
6.3.5. Others
6.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product
7. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
7.3.1. Oral
7.3.2. Intravenous
7.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration
8. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel
9. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Region
10. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
10.2.1. Buphenyl
10.2.2. Ravicti
10.2.3. Ammonul
10.2.4. Dietary Supplements
10.2.5. Others
10.3. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
10.3.1. Oral
10.3.2. Intravenous
10.4. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
11.2.1. Buphenyl
11.2.2. Ravicti
11.2.3. Ammonul
11.2.4. Dietary Supplements
11.2.5. Others
11.3. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
11.3.1. Oral
11.3.2. Intravenous
11.4. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
12.2.1. Buphenyl
12.2.2. Ravicti
12.2.3. Ammonul
12.2.4. Dietary Supplements
12.2.5. Others
12.3. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
12.3.1. Oral
12.3.2. Intravenous
12.4. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
13.2.1. Buphenyl
13.2.2. Ravicti
13.2.3. Ammonul
13.2.4. Dietary Supplements
13.2.5. Others
13.3. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
13.3.1. Oral
13.3.2. Intravenous
13.4. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
14.2.1. Buphenyl
14.2.2. Ravicti
14.2.3. Ammonul
14.2.4. Dietary Supplements
14.2.5. Others
14.3. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
14.3.1. Oral
14.3.2. Intravenous
14.4. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share/Position Analysis, by Company (2019)
15.3. Company Profiles
15.3.1. Abbott
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Nutricia (Danone Group)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Mead Johnson (Reckitt Benckiser)
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Horizon Therapeutics plc
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Nestlé
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Bausch Health Companies, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Ultragenyx Pharmaceutical Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Arcturus Therapeutics, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Acer Therapeutics
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
Shibuya Data Count is a reseller offering a variety of market research reports from different industries, provided by a global team of experienced research professionals who ensure the most reliable and up-to-date research analysis reports.